Samsung Biologics plans IPO this year, seen worth as much as $2.6 billion

SEOUL (Reuters) - Samsung Biologics Co Ltd, a contract manufacturer of biotech drugs for global pharmaceutical firms, said it was planning an IPO this year, an offering that analysts have estimated...